AR059622A1 - Quinolonas utiles como inhibidores de la sintetasa del oxido nitrico inducibles - Google Patents
Quinolonas utiles como inhibidores de la sintetasa del oxido nitrico induciblesInfo
- Publication number
- AR059622A1 AR059622A1 ARP070100770A ARP070100770A AR059622A1 AR 059622 A1 AR059622 A1 AR 059622A1 AR P070100770 A ARP070100770 A AR P070100770A AR P070100770 A ARP070100770 A AR P070100770A AR 059622 A1 AR059622 A1 AR 059622A1
- Authority
- AR
- Argentina
- Prior art keywords
- heteroaryl
- heterocycloalkyl
- optionally substituted
- cycloalkyl
- aryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Quinolonas de la formula 1 que inhiben la sintasa NOS inducible conjuntamente con los métodos de sintetizacion y uso de los compuestos, incluyendo métodos de inhibicion o modulacion de síntesis del oxido nítrico y/o disminucion de los niveles de oxido nítrico en un paciente mediante la administracion de los compuestos para el tratamiento de enfermedades. Reivindicacion 1: Un método para lograr un efecto en un paciente caracterizado porque comprende la administracion a un paciente de una cantidad terapéuticamente efectiva de un compuesto de la formula 1, o una sal, éster, o prodroga del mismo, en donde: R1 se selecciona desde el grupo que consta de acil, alquiIo, alquileno, aminoalquilo, amidoalquilo, alquinilo, amido, amino, aminoalquilo, arilo, ariloalquilo, ariloalcoxi, ariloamino, ariltio, carboxilo, cicloalquilo, éster, éter, halo, haloalcoxi, haloalquilo, heteroarilo, heteroariloalquilo, heteroariloamino, heterocicloalquilo, heterocicloalquilalquilo, hidrazinil, hidrogeno, imino, tio, sulfonato, sulfonilamino y sulfonilaminoalquilo, cualquiera de los cuales puede sustituirse opcionalmente; R2 se selecciona del grupo que consta de acil, alcoxi, alcoxialquilo, alquilo, alquileno, alquiloamino, alquinilo, alquilimino, amido, amino, arilo, carboxi, ciano, cicloalquilo, éster, halo, haloalquilo, heteroarilo, heterocicloalquilo e hidrogeno, cualquiera de los cuales pueden sustituirse opcionalmente; o, alternativamente, R2 puede combinar con R1 para formar heterocicloalquilo, el cual puede sustituirse opcionalmente; R3 se selecciona desde el grupo que consta de alquilo, amino, ariloalquilo, arilo, cicloalquilo, haloalquilo, heteroariloalquilo, heterocicloalquilo e hidrogeno, cualquiera de los cuales pueden sustituirse opcionalmente; y A, B, C y D se seleccionan independientemente cada uno desde el grupo que consta de acil, alcoxi, alquilo, alquileno, alquiloamino, alquinil, amido, amino, aminosulfonil, arilo, ariloalcoxi, ariloamino, ariltio, carboxi, cicloalquilo, éster, éter, halo, haloalcoxi, haloalquilo, heteroarilo, heteroariloamino, heterocicloalquilo, hidrazinil, hidrogeno, imino, tio, sulfonato y sulfonilamino, cualquiera de los cuales pueden sustituirse opcionalmente; o, alternativamente, cualquiera de los dos o más A, B, C y D pueden combinarse para formar arilo, cicloalquilo, heteroarilo o heterocicloalquilo, cualquiera de los cuales pueden sustituirse opcionalmente; Y en donde el efecto se selecciona del grupo que consiste de la inhibicion de iNOS y el tratamiento de una enfermedad mediada por lnos en un paciente en necesidad del mismo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US77656106P | 2006-02-24 | 2006-02-24 | |
US84869606P | 2006-10-02 | 2006-10-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR059622A1 true AR059622A1 (es) | 2008-04-16 |
Family
ID=38581716
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070100770A AR059622A1 (es) | 2006-02-24 | 2007-02-23 | Quinolonas utiles como inhibidores de la sintetasa del oxido nitrico inducibles |
Country Status (12)
Country | Link |
---|---|
US (1) | US20080139558A1 (es) |
EP (1) | EP1986747A2 (es) |
JP (1) | JP2009529496A (es) |
KR (1) | KR20080108478A (es) |
AR (1) | AR059622A1 (es) |
AU (1) | AU2007235132A1 (es) |
BR (1) | BRPI0707028A2 (es) |
CA (1) | CA2643011A1 (es) |
IL (1) | IL193526A0 (es) |
MX (1) | MX2008010931A (es) |
TW (1) | TW200803855A (es) |
WO (1) | WO2007117778A2 (es) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2591784B1 (en) | 2005-05-10 | 2016-09-14 | Intermune, Inc. | Pyridine-2-one-derivatives as modulators of stress-activated protein kinase system |
MX2008012404A (es) * | 2006-03-28 | 2008-10-09 | Novartis Ag | Derivados de amida y su aplicacion para el tratamiento de enfermedades relacionadas con proteina-g. |
WO2008103615A1 (en) * | 2007-02-21 | 2008-08-28 | Kalypsys, Inc. | Isoquinolines useful as inducible nitric oxide synthase inhibitors |
WO2008113006A1 (en) * | 2007-03-14 | 2008-09-18 | Xenon Pharmaceuticals Inc. | Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions |
CL2008002241A1 (es) | 2007-07-31 | 2009-12-28 | Bayer Cropscience Sa | Compuestos derivados de (hetero)aril-metilen-n-cicloalquil carboxamida condensados de 6 elementos con n-sustituido; composicion funguicida que comprende uno de dichos compuestos; y metodo para el control hongos fitopatogenos de cultivos agricolas. |
WO2009029625A1 (en) * | 2007-08-27 | 2009-03-05 | Kalypsys, Inc. | 4- [heterocyclyl-methyl] -8-fluoro-quinolin-2-ones useful as nitric oxide synthase inhibitors |
WO2009029617A1 (en) * | 2007-08-27 | 2009-03-05 | Kalypsys, Inc. | Diarylamine-substituted quinolones useful as inducible nitric oxide synthase inhibitors |
TW200924772A (en) * | 2007-08-27 | 2009-06-16 | Kalypsys Inc | Heterobicyclic-substituted quinolones useful as nitric oxide synthase inhibitors |
CN101952273B (zh) | 2008-02-12 | 2014-11-12 | 柳韩洋行 | 2-甲基2’-苯基丙酸衍生物的制备方法和中间体化合物 |
CA2726588C (en) | 2008-06-03 | 2019-04-16 | Karl Kossen | Compounds and methods for treating inflammatory and fibrotic disorders |
WO2010056564A1 (en) * | 2008-11-13 | 2010-05-20 | Merck Sharp & Dohme Corp. | Quinolone neuropeptide s receptor antagonists |
CA2803842C (en) | 2010-06-30 | 2020-01-07 | Fujifilm Corporation | Nicotinamide derivative or salt thereof as syk-inhibitors |
AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
CN103121969A (zh) * | 2012-12-04 | 2013-05-29 | 中国科学院昆明植物研究所 | 苯并咪唑及其衍生物,其药物组合物及其应用 |
CN103121970B (zh) * | 2012-12-04 | 2015-04-29 | 中国科学院昆明植物研究所 | 苯并咪唑及其衍生物,其药物组合物及其在制备抗抑郁药物中的应用 |
MX2016012808A (es) | 2014-04-02 | 2017-01-05 | Intermune Inc | Piridinonas anti-fibroticas. |
SG11201607795UA (en) | 2014-04-08 | 2016-10-28 | Methodist Hospital | Inos-inhibitory compositions and their use as breast cancer therapeutics |
AU2015317327B9 (en) * | 2014-09-19 | 2020-04-09 | Forma Therapeutics, Inc. | Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
CA2961807A1 (en) | 2014-09-19 | 2016-03-24 | Forma Therapeutics, Inc. | Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
ES2768694T3 (es) | 2014-09-19 | 2020-06-23 | Forma Therapeutics Inc | Composiciones de quinolinona pirimidinas como inhibidores de isocitrato dehidrogenasa mutante |
SG11201702194SA (en) * | 2014-09-19 | 2017-04-27 | Forma Therapeutics Inc | Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
WO2016171756A1 (en) | 2015-04-21 | 2016-10-27 | Forma Therapeutics, Inc. | Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors |
WO2016171755A1 (en) | 2015-04-21 | 2016-10-27 | Forma Therapeutics, Inc. | Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
GB201512635D0 (en) | 2015-07-17 | 2015-08-26 | Ucl Business Plc | Uses of therapeutic compounds |
US11013733B2 (en) | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1) |
US11311527B2 (en) | 2018-05-16 | 2022-04-26 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) |
WO2019222551A1 (en) | 2018-05-16 | 2019-11-21 | Forma Therapeutics, Inc. | Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
US11013734B2 (en) | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation |
EP3720442B1 (en) | 2018-05-16 | 2022-12-28 | Forma Therapeutics, Inc. | Inhibiting mutant idh-1 |
CN110903267B (zh) * | 2018-09-14 | 2023-09-22 | 中国科学院宁波材料技术与工程研究所 | 一种含(四氢)呋喃取代基的烯酸化合物的合成方法 |
US20230076506A1 (en) * | 2019-12-11 | 2023-03-09 | Ryvu Therapeutics S.A. | Heterocyclic compounds as modulators of stimulator of interferon genes (sting) |
CN116507627A (zh) | 2020-11-02 | 2023-07-28 | 勃林格殷格翰国际有限公司 | 作为egfr抑制剂的经取代1h-吡唑并[4,3-c]吡啶及衍生物 |
WO2022260648A1 (en) * | 2021-06-07 | 2022-12-15 | Uwm Research Foundation, Inc. | Use of substituted 5-(4-methyl-6-phenyl-4h-benzo[f]imidazo[1,5-a][1,4] diazepin-3-yl)-1,2,4-oxadiazoles in the treatment of inflammatory conditions |
WO2023248193A1 (en) * | 2022-06-24 | 2023-12-28 | Zydus Lifesciences Limited | Treatment for glomerular diseases |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5929668A (ja) * | 1982-08-13 | 1984-02-16 | Otsuka Pharmaceut Co Ltd | カルボスチリル誘導体 |
JPS60142959A (ja) * | 1983-12-28 | 1985-07-29 | Otsuka Pharmaceut Co Ltd | キノリン誘導体 |
JPS6463518A (en) * | 1987-09-02 | 1989-03-09 | Otsuka Pharma Co Ltd | Antiarrhythmic agent |
FR2637591B1 (fr) * | 1988-10-11 | 1992-10-23 | Synthelabo | Derives de quinoleinone, leur preparation et leur application en therapeutique |
JP3122671B2 (ja) * | 1990-05-23 | 2001-01-09 | 協和醗酵工業株式会社 | 複素環式化合物 |
US5457099A (en) * | 1992-07-02 | 1995-10-10 | Sawai Pharmaceutical Co., Ltd. | Carbostyril derivatives and antiallergic agent |
ES2094567T3 (es) * | 1992-10-27 | 1997-01-16 | Janssen Pharmaceutica Nv | Derivados de la 4-quinolinilo con actividad anti-helicobacter. |
JPH06239858A (ja) * | 1993-02-16 | 1994-08-30 | Otsuka Pharmaceut Co Ltd | 末梢血管拡張剤 |
US6235748B1 (en) * | 1997-09-03 | 2001-05-22 | Guilford Pharmaceuticals Inc. | Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity |
AU4738101A (en) * | 2000-03-17 | 2001-10-03 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
MXPA03002032A (es) * | 2000-09-11 | 2003-07-24 | Chiron Corp | Derivados de quinolinona. |
JP4351445B2 (ja) * | 2000-12-27 | 2009-10-28 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ファルネシルトランスフェラーゼを阻害する4−置換−キノリンおよびキナゾリン誘導体 |
JP2003146972A (ja) * | 2001-11-14 | 2003-05-21 | Teikoku Hormone Mfg Co Ltd | カルボスチリル誘導体 |
EP3424926A1 (de) * | 2002-08-21 | 2019-01-09 | Boehringer Ingelheim Pharma GmbH & Co. KG | 8-[3-amino-piperidin-1-yl]-xanthine, deren herstellung und deren verwendung als arzneimittel |
WO2004078731A1 (fr) * | 2003-03-06 | 2004-09-16 | 'chemical Diversity Research Institute', Ltd. | Acides quinoline-carboxyliques et leurs derives et bibliotheque focalisee |
EP1725235B1 (en) * | 2004-02-05 | 2009-04-15 | Schering Corporation | Piperidine derivatives useful as ccr3 antagonists |
-
2007
- 2007-02-16 TW TW096106270A patent/TW200803855A/zh unknown
- 2007-02-23 CA CA002643011A patent/CA2643011A1/en not_active Abandoned
- 2007-02-23 AU AU2007235132A patent/AU2007235132A1/en not_active Abandoned
- 2007-02-23 BR BRPI0707028-4A patent/BRPI0707028A2/pt not_active Application Discontinuation
- 2007-02-23 EP EP07757450A patent/EP1986747A2/en not_active Withdrawn
- 2007-02-23 WO PCT/US2007/062769 patent/WO2007117778A2/en active Application Filing
- 2007-02-23 JP JP2008556576A patent/JP2009529496A/ja active Pending
- 2007-02-23 KR KR1020087023220A patent/KR20080108478A/ko not_active Application Discontinuation
- 2007-02-23 AR ARP070100770A patent/AR059622A1/es unknown
- 2007-02-23 US US11/678,572 patent/US20080139558A1/en not_active Abandoned
- 2007-02-23 MX MX2008010931A patent/MX2008010931A/es unknown
-
2008
- 2008-08-18 IL IL193526A patent/IL193526A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2643011A1 (en) | 2007-10-18 |
US20080139558A1 (en) | 2008-06-12 |
IL193526A0 (en) | 2009-08-03 |
WO2007117778A9 (en) | 2009-05-22 |
AU2007235132A1 (en) | 2007-10-18 |
TW200803855A (en) | 2008-01-16 |
BRPI0707028A2 (pt) | 2011-04-12 |
MX2008010931A (es) | 2008-09-03 |
WO2007117778A8 (en) | 2008-12-31 |
WO2007117778A2 (en) | 2007-10-18 |
EP1986747A2 (en) | 2008-11-05 |
WO2007117778A3 (en) | 2008-02-07 |
JP2009529496A (ja) | 2009-08-20 |
KR20080108478A (ko) | 2008-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR059622A1 (es) | Quinolonas utiles como inhibidores de la sintetasa del oxido nitrico inducibles | |
DK2091948T3 (da) | Nye inhibitorer af glutaminylcyclase | |
AR062074A1 (es) | Derivados de alcoholes 1-fenil-2-piridinil alquilenicos como inhibidores de fosfodiesterasa | |
PE20160608A1 (es) | Compuestos de quinolina selectivamente sustituida | |
BRPI1009333B8 (pt) | compostos inibidores de beta-secretase, seus usos, bem como composição farmacêutica | |
AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
RS53839B1 (en) | SPIROCYCLES AS INHIBITORS OF 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE 1 | |
RS54260B1 (en) | AMINODIHYDROTIAZINE DERIVATIVES AS BACE INHIBITORS FOR ALZHEIMER DISEASE TREATMENT | |
AR056964A1 (es) | Derivados de aminosulfonilo, composiciones farmaceuticas y sus usos | |
AR056536A1 (es) | Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace) | |
CR20110616A (es) | Derivados amino-propiónicos sustituidos como inhibidores de neprilisina | |
AR062797A1 (es) | Derivados de piperidina como inhibidores de renina, composiciones farmaceuticas. | |
EA200900924A1 (ru) | Циклизованные производные как ингибиторы eg-5 | |
MY169179A (en) | Novel piperidine compound or salt thereof | |
AR075951A1 (es) | Dihidropiridin sulfonamidas y dihidropiridin sulfamidas como inhibidores de mek | |
AR063577A1 (es) | Derivados 8- piperidinil - pirimido [1 2 a] pirimidin -6-ona y 8- piperidinil-2- pirimidinil- pirimido [1,2-a] pirimidin -6- ona sustituidos | |
RS53389B (en) | PHARMACEUTICAL UNITS | |
ES2570167T3 (es) | Derivados de benzimidazol como inhibidores de glutaminil ciclasa | |
EA201071012A1 (ru) | Производные азетидинов, способ их получения и применение их в терапии | |
EA201101621A1 (ru) | Производные бензоксазолона в качестве ингибиторов альдостеронсинтазы | |
RU2012146325A (ru) | Терапевтическое средство или профилактическое средство для лечения фибромиалгии | |
EA201270816A1 (ru) | Производные бензамида и их применение в качестве ингибиторов hsp90 | |
AR061185A1 (es) | Compuestos heterociclicos como inhibidores de hsp90. composiciones farmaceuticas. | |
PH12014501181A1 (en) | N- (4 -quinolinylmethyl) sulfonamide derivatives and their use as anthelmintics | |
JP2016500653A5 (es) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |